CKD Clinical Trials: Plain-Language Summaries of the Evidence That Changed Nephrology

Source: NEJM, Lancet, KDIGO 2024 Reviewed by: CKDPartner Clinical Team Updated: June 2026

The last decade has transformed CKD management through five landmark trials. DAPA-CKD and EMPA-KIDNEY established SGLT2 inhibitors as kidney-protective for all causes of CKD. CREDENCE confirmed the effect with canagliflozin in diabetic CKD. FIDELIO-DKD and FIGARO-DKD established finerenone as the third pillar alongside RAASi and SGLT2i. These results drove the KDIGO 2024 guideline update.

At-a-Glance: 5 Landmark Trials

TrialDrugPrimary ReductionHR (95% CI)Journal / Year
DAPA-CKDDapagliflozin 10 mg39% ↓ CKD progression + death0.61 (0.51–0.72)NEJM 2020
EMPA-KIDNEYEmpagliflozin 10 mg28% ↓ kidney progression + CV death0.72 (0.64–0.82)NEJM 2023
CREDENCECanagliflozin 100 mg34% ↓ composite CKD endpoint0.66 (0.53–0.81)NEJM 2019
FIDELIO-DKDFinerenone 10–20 mg18% ↓ kidney composite0.82 (0.73–0.93)NEJM 2020
FIGARO-DKDFinerenone 10–20 mg13% ↓ CV composite0.87 (0.76–0.98)NEJM 2021

DAPA-CKD Trial (2020) — The Non-Diabetic CKD Breakthrough

SGLT2 Inhibitor

Dapagliflozin 10 mg in CKD — Diabetic AND Non-Diabetic

39% reduction in CKD progression or death
HR 0.61 (95% CI 0.51–0.72) | p<0.001 | NNT = 19 over 2.4 years

Heerspink HJL et al. NEJM 2020;383:1436–1446. PMID: 32970396

EMPA-KIDNEY Trial (2023) — Very Low eGFR Coverage

SGLT2 Inhibitor

Empagliflozin 10 mg — Down to eGFR 20

28% reduction in kidney progression or CV death
HR 0.72 (95% CI 0.64–0.82) | p<0.001 | 6,609 participants

The EMPA-KIDNEY Collaborative Group. NEJM 2023;388:117–127. PMID: 36331190

CREDENCE Trial (2019) — The First SGLT2i CKD Trial

SGLT2 Inhibitor

Canagliflozin 100 mg in Diabetic CKD with Heavy Proteinuria

34% reduction in CKD composite endpoint
HR 0.66 (95% CI 0.53–0.81) | p=0.00001 | Trial stopped early for benefit

Perkovic V et al. NEJM 2019;380:2295–2306. PMID: 30990260

FIDELIO-DKD & FIGARO-DKD — Finerenone's Dual Protection

Non-Steroidal MRA

Finerenone — Kidney + Cardiovascular Protection in Diabetic CKD

FIDELIO: 18% kidney ↓ | FIGARO: 13% CV ↓
FIDELIO HR 0.82 (0.73–0.93) | FIGARO HR 0.87 (0.76–0.98)

Bakris GL et al. (FIDELIO) NEJM 2020;383:2219–2229. | Pitt B et al. (FIGARO) NEJM 2021;385:2252–2263.

🧬 Apply This Evidence to Your CKD — Free

CKDPartner's multi-LLM deliberation engine interprets your lab values against these trial populations to answer whether you may benefit from SGLT2i, Finerenone, or RAASi initiation.

Open CKDPartner Clinical Deliberation →

Frequently Asked Questions

What did the DAPA-CKD trial prove?

DAPA-CKD (NEJM 2020) proved dapagliflozin reduces CKD progression by 39% (HR 0.61) and all-cause mortality by 31% — in both diabetic and non-diabetic CKD patients. This was the first trial to confirm SGLT2i benefit beyond diabetes, establishing their use across all CKD causes.

What is the EMPA-KIDNEY trial?

EMPA-KIDNEY (NEJM 2023) showed empagliflozin reduces kidney progression by 28% (HR 0.72) in patients with eGFR as low as 20. It extended SGLT2i benefit to the broadest CKD population yet, including non-diabetic patients down to very low eGFR.

What did FIDELIO-DKD show?

FIDELIO-DKD (NEJM 2020) established finerenone as a kidney- and heart-protective drug in diabetic CKD, reducing kidney composite by 18% (HR 0.82) on top of RAASi. It is now the basis for KDIGO 2024's recommendation to add finerenone as the third pillar of CKD + T2DM therapy.